Diabetology: our cornerstone

Partners with companies, scientific societies, patient associations, institutions

Diabetology: our cornerstone
In its thirty years of activity in the field of diabetology, HCC has played a leading role in communication. Since Humalog's introduction in 1997, HCC has collaborated with leading companies, such as Lilly, Novo Nordisk, Roche, and Medtronic, as well as major scientific and patient associations. HCC has promoted cutting-edge editorial projects, such as the Corriere Salute Diabetes Forum and the Diabetologia33 newsletter. It also handles communications for the Parliamentary Intergroup dedicated to obesity, diabetes, and non-communicable diseases. This confirms HCC's constant and qualified presence in the Italian diabetes information landscape.

Modern diabetology was born in Toronto, Canada, in November 1920. A young doctor named Frederick Banting asked for an appointment with Professor John James Rickard Macleod, a distinguished figure at the local university. Banting wanted help with his research on pancreatic extract. He received a laboratory and an assistant. July 31, 1921, a hot summer Saturday, was a turning point in the history of diabetes. Banting and his assistant, Charles H. Best, administered pancreatic extract from a healthy dog to a dog without pancreas. The experiment was successful. From there, studies continued, leading Banting to refine his discovery. On January 11, 1922, finally, Dr. Walter R. Campbell injected Banting and Best's preparation into a 14-year-old teenager named Leonard Thompson. Unaware that he was making history, Thompson became the first person with diabetes to be treated with the new drug, insulin. This is the story of the life-saving hormone whose discovery changed the course of type 1 diabetes, a disease with a fatal prognosis until 1921. Now, it is a condition with which people can live and lead normal lives.

Diabetes, 30 years of HCC's constant presence on the market

We started working in diabetology in 1997, by launching Humalog (Lilly), the first fast-acting human insulin analogue, in Italy. Since 2010, we have been a partner of Novo Nordisk. Since 2003, we have been collaborating with the world's leading diabetes organizations: Fand (Italian Diabetes Association), Diabete Italia, EASD (European Association for the Study of Diabetes), SID (Italian Society of Diabetology), AMD (Association of Diabetologists), and FESDI (Federation of Italian Diabetology Societies). From 2016 to 2024, we managed communications for Roche Diabetes Care. Currently, we do the same for Medtronic. We have also worked with Ascensia, Bruno Farmaceutici, Lifescan, Merck, Meteda, MSD, Ypsomed, and many others. In 2011, we established he Corriere della Sera diabetes Forum in collaboration with AMD. In 2012, we created the Diabetologia33 newsletter for specialists, with Edra and AMD, and produced it for many years. Since its establishment in the last legislature, we have been responsible for communications for the Parliamentary Intergroup on Obesity, Diabetes, and Non-Communicable Diseases.
Share

Let's start a relationship

Whether you want to build a project together or ask us a question, the first step for us is the relationship.